Use and Safety of Gadolinium Based Contrast Agents in Pediatric MR Imaging
- 218 Downloads
Gadolinium-based contrast agents (GBCA) used for MR imaging are a valuable imaging resource that has benefited patient management over last three decades and largely have a high safety profile. However, recently, adverse effects related to GBCA like nephrogenic systemic fibrosis (NSF) and asymptomatic gadolinium deposition in tissues including brain are concerning. While NSF has largely stopped occurring due to precautions and guidelines to not use GBCA in patients with poor renal function, the long term effects of gadolinium deposition, especially in brain, are not known at this stage. Cautious approach needs to be taken with risk-benefit analysis in each patient to avoid its administration when not necessary. In this review, authors discuss basics of gadolinium, mechanism of enhancement, agents in clinical use and safety issues, and in the end, offer some solutions for safety concerns.
KeywordsGadolinium-based contrast agents MRI NSF Gadolinium deposition Children
All authors contributed to literature search, writing the manuscript and review of the manuscript. GBC will act as guarantor for this paper.
Compliance with Ethical Standards
Conflict of Interest
GBC received Moderator Honararium in 2018 from Bayer Inc.
Source of Funding
- 8.Tweedle MF, Kanal E. Muller R. Considerations in the selection of a new gadolinium-based contrast agents. Appl Radiol. 2014, May 12.Google Scholar
- 9.American College of Radiology Manual of Contrast Media Version 10.2. 2016. Available at: https://www.acr.org/Clinical-Resources/Contrast-Manual. Accessed 25 Aug 2018.
- 10.Bhargava R, Noga M. Safety and efficacy of gadobutrol-enhanced MRI in patients aged under 2 years-a single-center, observational study. Magn Reson Insights. 2013;6:1–12.Google Scholar
- 18.Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2014;270:834–41.Google Scholar
- 19.McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. 2015;275:772–82.Google Scholar
- 21.Gulani V, Calamante F, Shellock FG, Kanal E, Reeder SB; International Society for Magnetic Resonance in Medicine. Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol. 2017;16:564–70.Google Scholar